MAGELLAN LONGEVITY
HomeResearchStudy library › What is the efficacy and safety of inositols in treating Polycystic…
Study summary · General aging biology & healthspan

What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS) compared to metformin or placebo?

In one paragraph

Myo-Inositol, a randomized controlled trial (Reprod Biol Endocrinol 2023, PMID 36703143) — inositol treatment resulted in a 1.79 times higher risk of regular menstrual cycles compared to placebo (CI: 1.13; 2.85) and showed non-inferiority to metformin for this outcome. The abstract for Myo-Inositol states no limitations.

Source: Reprod Biol Endocrinol 2023, PMID 36703143 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

Reprod Biol Endocrinol · 2023 · PMID 36703143 · DOI 10.1186/s12958-023-01055-z

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Inositols are an effective and safe treatment for PCOS, showing similar benefits to metformin for many outcomes.

The question

What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS) compared to metformin or placebo?

What they tested

Inositols may be a potential alternative to metformin for treating PCOS, with comparable efficacy and safety.

How they did it

A systematic review was conducted by searching CENTRAL, MEDLINE, and Embase for randomized controlled trials (RCTs) from inception until October 20th, 2021. Eligible RCTs included women diagnosed with PCOS and compared any inositols with metformin or placebo. Primary outcome was cycle normalization, and secondary outcomes included BMI, carbohydrate metabolism parameters, and clinical/laboratory hyperandrogenism. Results were reported as risk ratios or mean differences (MDs) with 95% confidence intervals (CIs).

What they found

Twenty-six RCTs with 1691 patients were identified (806 inositol, 311 placebo, 509 metformin). Inositol treatment resulted in a 1.79 times higher risk of regular menstrual cycles compared to placebo (CI: 1.13; 2.85) and showed non-inferiority to metformin for this outcome. Compared to placebo, inositol treatment led to greater decreases in BMI (MD = -0.45), free testosterone (MD = -0.41), total testosterone (MD = -20.39), androstenedione (MD = -0.69), glucose (MD = -3.14), and AUC insulin (MD = -2081.05). Inositol also significantly increased sex-hormone-binding globulin compared to placebo (MD = 32.06).

Mean Differences of Inositol vs. Placebo in PCOS Outcomes
Values shown: Mean Difference
BMI-0.45
Free Testosterone-0.41
Total Testosterone-20.39
Androstenedione-0.69
Glucose-3.14
AUC Insulin-2081.05
SHBG32.06

Mean differences in various parameters when comparing inositol treatment to placebo in women with PCOS. Negative values indicate a decrease with inositol, while positive values indicate an increase.

What it means

Inositol is an effective and safe treatment for PCOS. It demonstrated non-inferiority to metformin in most outcomes.

Limitations

The abstract does not explicitly state limitations of the systematic review itself, beyond the scope of the included studies.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Inositol is an effective and safe treatment in PCOS”— from the published abstract, Reprod Biol Endocrinol 2023

The paper at a glance

Magellan’s evidence labelinsulin second-messenger (our label for this citation — see PubMed for the paper’s own title and authors)
JournalReprod Biol Endocrinol
Year2023
PMID36703143 ↗
DOI10.1186/s12958-023-01055-z ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Myo-Inositol

In randomized trials and meta-analyses, myo-inositol (often combined with D-chiro-inositol) has been associated with improved insulin sensitivity—lower fasting insulin and HOMA-IR—restoration of menstrual regularity and ovulation in PCOS, and a reduced incidence of gestational diabetes (a Cochrane review found…

Myo-Inositol

Myo-inositol is a naturally occurring sugar-like compound (a cyclitol, the most abundant of nine…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS) compared to metformin or placebo? [Plain-English summary of Reprod Biol Endocrinol 2023, PMID 36703143, DOI 10.1186/s12958-023-01055-z]. Magellan Longevity. https://magellanlongevity.com/study/s131.html
BibTeX
@misc{magellan_s131, title = {What is the efficacy and safety of inositols in treating Polycystic Ovary Syndrome (PCOS) compared to metformin or placebo?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/s131.html}}, note = {Plain-English summary of PubMed PMID 36703143; DOI 10.1186/s12958-023-01055-z; Reprod Biol Endocrinol 2023. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/s131.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 36703143 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.